RxSight/$RXST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Ticker
$RXST
Sector
Primary listing
Employees
498
Headquarters
Website
RxSight Metrics
BasicAdvanced
$357M
-
-$0.80
1.15
-
Price and volume
Market cap
$357M
Beta
1.15
52-week high
$58.23
52-week low
$6.32
Average daily volume
1.3M
Financial strength
Current ratio
13.927
Quick ratio
12.537
Long term debt to equity
3.818
Total debt to equity
4.214
Interest coverage (TTM)
-2,025.33%
Profitability
EBITDA (TTM)
-39.323
Gross margin (TTM)
73.12%
Net profit margin (TTM)
-21.93%
Operating margin (TTM)
-28.92%
Effective tax rate (TTM)
-0.23%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-8.65%
Return on equity (TTM)
-11.66%
Valuation
Price to revenue (TTM)
2.396
Price to book
1.28
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
-16.873
Free cash flow yield (TTM)
-5.93%
Free cash flow per share (TTM)
-0.517
Growth
Revenue change (TTM)
27.68%
Earnings per share change (TTM)
-20.15%
3-year revenue growth (CAGR)
62.12%
3-year earnings per share growth (CAGR)
-31.40%
What the Analysts think about RxSight
Analyst ratings (Buy, Hold, Sell) for RxSight stock.
Bulls say / Bears say
Light Adjustable Lens (LAL) procedure volume grew 13% year-over-year in Q2 2025, leading to a favorable product mix that boosted gross margin to 74.9% (Reuters).
RxSight increased its installed base of Light Delivery Devices (LDDs) by 34% year-over-year to 1,084 units in Q2 2025, expanding its network of cataract surgeons and practices (Reuters).
In Q2 2025, RxSight gained FDA approval to expand the LAL dioptric power range and launched its Light Adjustable Lens system in South Korea and Singapore, broadening its market presence (RxSight, Inc.).
Q2 2025 revenue dropped 4% from a year ago to $33.6 million and fell 11% compared to the previous quarter, coming in below company forecasts and signaling weaker demand for its premium IOL system (RxSight, Inc.).
Sales of Light Delivery Devices (LDDs) plunged 49% year-over-year and 45% sequentially in Q2 2025, sharply reducing upfront capital equipment revenue and pointing to a drop-off in adoption of the LDD system (RxSight, Inc.).
The company cut its full-year 2025 revenue guidance to $120–130 million from $160–175 million, a reduction of about 25–30%, signaling major growth headwinds ahead (Investopedia).
Data summarised monthly by Lightyear AI. Last updated on 12 Aug 2025.
RxSight Financial Performance
Revenues and expenses
RxSight Earnings Performance
Company profitability
RxSight News
AllArticlesVideos
RXST INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Business Wire·4 weeks ago
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
Business Wire·4 weeks ago
Deadline Approaching: RxSight, Inc. (RXST) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RxSight stock?
RxSight (RXST) has a market cap of $357M as of August 22, 2025.
What is the P/E ratio for RxSight stock?
The price to earnings (P/E) ratio for RxSight (RXST) stock is 0 as of August 22, 2025.
Does RxSight stock pay dividends?
No, RxSight (RXST) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next RxSight dividend payment date?
RxSight (RXST) stock does not pay dividends to its shareholders.
What is the beta indicator for RxSight?
RxSight (RXST) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.